Yarrow Bioscience (YARW) Capital Expenditures (2017 - 2021)
Yarrow Bioscience's (YARW) quarterly Capital Expenditures came in at $376000.0 in Q4 2021, up 210.26% on a QoQ basis from -$341000.0 in Q3 2021.
Yarrow Bioscience (YARW) Capital Expenditures (2017 - 2021) Analysis & Trends
Yarrow Bioscience (YARW) has 5 years of Capital Expenditures data on file, last reported at $376000.0 in Q4 2021.
- Quarterly Capital Expenditures changed N/A year-over-year to $376000.0 in Q4 2021, while the trailing twelve-month figure through Sep 2022 was $376000.0 (up 130.9% YoY) and the FY2024 annual result came in at $117000.0, changed N/A from the prior year.
- Capital Expenditures climbed to $376000.0 in Q4 2021, from -$341000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $934000.0 in Q4 2019 to a low of -$472000.0 in Q2 2021.
- A 5-year average of $55400.0 and a median of $71000.0 in 2020 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2018 — Capital Expenditures jumped 228.79% — and 2021, when it slumped 1061.9%.
- Tracing YARW's Capital Expenditures over 5 years: stood at -$66000.0 in 2017, then surged by 780.3% to $449000.0 in 2018, then soared by 108.02% to $934000.0 in 2019, then plunged by 92.4% to $71000.0 in 2020, then surged by 429.58% to $376000.0 in 2021.
- The last three Capital Expenditures figures came in at $376000.0 (Q4 2021), -$341000.0 (Q3 2021), and -$472000.0 (Q2 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Yarrow Bioscience | 32.54 Mn | 9.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 376,000.00 |
| Dec 31, 2021 | 376,000.00 |
| Sep 30, 2021 | -341,000.00 |
| Sep 30, 2021 | -341,000.00 |
| Jun 30, 2021 | -472,000.00 |
| Jun 30, 2021 | -472,000.00 |
| Mar 31, 2021 | -404,000.00 |
| Mar 31, 2021 | -404,000.00 |
| Jun 30, 2020 | 71,000.00 |
| Jun 30, 2020 | 71,000.00 |
| Mar 31, 2020 | 42,000.00 |
| Mar 31, 2020 | 42,000.00 |
| Dec 31, 2019 | 934,000.00 |
| Dec 31, 2019 | 934,000.00 |
| Sep 30, 2019 | -330,000.00 |
| Sep 30, 2019 | -330,000.00 |
| Jun 30, 2019 | 316,000.00 |
| Jun 30, 2019 | 316,000.00 |
| Mar 31, 2019 | 138,000.00 |
| Mar 31, 2019 | 138,000.00 |